CTS Accredited Webinars

A Role for Digital Health in the Behaviour Change Challenges Associated with the Management of Chronic Lung Disease in Canada

Date: Tuesday, September 29, 2020
Time: 4:00 pm – 5:00 pm EDT

The session will first describe the current state of chronic lung disease management in Canada, with a focus on the challenges of behaviour change and how patient attitudes, values, and beliefs influence this. We will then review how important barriers to behaviour change are identified and discuss different strategies to overcome them, linking this to behaviour change theory. Next, the role of digital health as a tool to help overcome barriers to behaviour change in the management of chronic lung disease in Canada will be presented. We will review how digital health can augment the provision of virtual care, support patient self-assessment and goal setting, and provide real-time individualized behaviour change interventions and reinforcement, as well as important feedback to both patients and their providers.

At the end of the session, participants will be able to;

Describe the current state of digital health in the management of chronic lung disease in Canada
Discuss the challenges of behaviour change associated with the management of chronic lung disease
Understand how digital health can help overcome behaviour change challenges to enhance management of chronic lung disease

CanMEDs Competencies addressed:
Communicator, Health Advocate, Leader, Scholar

Presenter:
Andrew Kouri, MD, FRCPC, St. Michael’s Hospital, Unity Health Toronto, Toronto, ON

Originally from Montreal, Dr. Kouri undertook his medical studies at McGill University, after which he completed residency training in General Internal Medicine and Adult Respirology at the University of Toronto. Since finishing his clinical training, he has been working towards obtaining his PhD in Clinical Epidemiology and Health Services Research at UofT. Both his research and clinical work focus on patients with chronic airways disease (asthma and COPD), and he is currently studying ways in which mobile digital health tools can be better designed and implemented for older patients with airways disease.

Moderator:
Samir Gupta, MD, FRCPC, University of Toronto, Toronto, ON

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program (MOC) of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Thoracic Society. You may claim a maximum of 1 hour (credits are automatically calculated).

This session is developed by the Canadian Thoracic Society with an independent educational grant from BreatheSuite and is planned to achieve scientific integrity, objectivity and balance.

Past Webinars

Are all inhaled corticosteroids (ICS) created equally?

June 17, 2020 Webinar: Dr. Cockcroft’s Presentation

Presenter: Donald Cockcroft, MD, FRCPC, University of Saskatchewan, Saskatoon, SK
Moderator: Andréanne Côté, MD, FRCPC, Quebec Heart and Lung Institute, Université Laval, Quebec City, QC

The presentation will review the history of inhaled corticosteroid (ICS) use in asthma from early use of cortisone acetate powder in the 1950s to the first commercial ICS MDI (BDP) in the 1970s, up to more recently introduced ICS. It will concentrate on the evolution of ICS structural features as it relates to potency and therapeutic index.

Learning Objectives
At the end of this presentation, attendees will be able to:

Summarize data supporting older and modern ICS medications in asthma and how steroids evolved since the 1970s.
Re-evaluate the concept of ICS dose equivalence – what evidence supports low, med, high dose ICS?
Discuss the unique structural features of older and modern ICS, the concept of steroid potency, therapeutic index, and its clinical impact.

Presenter:
Donald Cockcroft, MD, FRCPC, University of Saskatchewan, Saskatoon, SK

Dr. Donald Cockcroft trained with Freddy Hargreave (1975-1977) in respirology and allergy research predominantly asthma. He has worked in academic respiratory medicine at the University of Saskatchewan for 43 years with clinical practice and research focussing on asthma. His area of research interest is mainly bronchoprovocation with allergen, methacholine, mannitol and other stimuli.

Moderator:
Andréanne Côté, MD, FRCPC, Quebec Heart and Lung Institute, Université Laval, Quebec City, QC

This session is developed by the Canadian Thoracic Society with an independent educational grant from GSK and is planned to achieve scientific integrity, objectivity and balance.

PF-ILD in the Canadian Landscape: Sharing Best Practices in Management

June 2, 2020 Webinar: Dr. Kolb’s Presentation

Presenter: Martin Kolb, MD, PhD, McMaster University, Hamilton, ON
Moderator: Maggie Larché, MD, MRCP(UK), PhD, McMaster University, Hamilton, ON

IPF is a progressive disease with high morbidity and mortality. The past years have brought significant improvements in the pharmacological therapy of IPF, but disease progression nevertheless occurs in most patients, albeit at a slower rate. This means that symptomatic treatment of patients with IPF (and other fibrotic lung disorders) remains a major element of patient care.

Learning Objectives
At the end of this presentation, attendees will be able to:

Explain the unmet clinical need around PF-ILD;
Evaluate emerging evidence in PF-ILD treatments, specifically connective tissue disease-related ILDs (CTD-ILD);
Discuss best practice approaches for collaborative care in the diagnosis and monitoring of CTD‑ILD.
Discuss the possible impact of Covid-19 on PF-ILD

CanMEDs Competencies addressed:
Health Advocate, Medical Expert, Professional, Scholar

Presenter:
Martin Kolb, MD, PhD, Professor, Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON

Dr. Martin Kolb is the Moran Campbell Chair and Professor in respiratory medicine and Director of the Division of Respirology, McMaster University. His major research interests are fibrotic lung disease, with a particular interest in the role of growth factors and matrix abnormalities in disease progression. He leads activities in biomarker development for lung fibrosis and is a principal investigator and steering committee member in numerous ILD clinical trials. Professor Kolb has authored over 130 peer-reviewed publications on different basic science and clinical topics. He is the Chief-Editor of the European Respiratory Journal (2018-2023).

Moderator:
Maggie Larché, MD, MRCP(UK), PhD, Associate Professor, Departments of Medicine and Pediatrics, Divisions of Rheumatology, and Clinical Immunology and Allergy, McMaster University, Hamilton, ON

This session was developed by the Canadian Thoracic Society with an independent educational grant from Boehringer Ingelheim and was planned to achieve scientific integrity, objectivity and balance.